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ABSTRACT: The perfect separation with optimal productivity, yield, and purity is very difficult to achieve. Despite its high
selectivity, in crystallization unwanted impurities routinely contaminate a crystallization product. Awareness of the mechanism by
which the impurity incorporates is key to understanding how to achieve crystals of higher purity. Here, we present a general
workflow which can rapidly identify the mechanism of impurity incorporation responsible for poor impurity rejection during a
crystallization. A series of four general experiments using standard laboratory instrumentation is required for successful
discrimination between incorporation mechanisms. The workflow is demonstrated using four examples of active pharmaceutical
ingredients contaminated with structurally related organic impurities. Application of this workflow allows a targeted problem-solving
approach to the management of impurities during industrial crystallization development, while also decreasing resources expended
on process development.
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■ INTRODUCTION
Crystallization is a highly selective separation and purification
technique used across the pharmaceutical industry.1 The
quality of a crystallization product is defined by four principal
attributes: chemical purity, polymorphic form, particle size, and
crystal morphology. Analyzing chemical purity is therefore of
critical importance during development of a crystallization
process. Ideally after crystallization, the resulting solid
particulate product is composed of one single target compound
with all other chemical entities remaining in the liquid phase
for disposal. In reality, the majority of the impurity is rejected
by the growing crystals, but some impurity compromises the
final product purity. Ranitidine is an example showing the
impact of an impure product: In 2019, the US Food and Drug
Administration recalled ranitidine, a common heartburn
medication, due to unacceptable levels of the known
carcinogen N-nitrosodimethylamine.2 Samples were found to
contain up to 9 times (0.86 μg) the recommend safe daily
ingestion level (0.096 μg) in a single 300 mg ranitidine dose.3
It is essential to remove residual impurity compounds to
below a threshold concentration value, as they could have
unwanted, even detrimental, biological effects above it.4
Coping with too high concentrations of impurities in
crystalline products can be challenging,5 and impurity rejection
is typically tackled on a case by case basis.6 Industry requires a
targeted approach, the methodology of which can be
transferred to any novel system. We present here a general
workflow to identify the mechanism of impurity incorporation
responsible for poor impurity rejection during crystallization
through four problem solving stages. Once the impurity
incorporation mechanism is identified, specific targeted
changes can be made to the process design in order to reduce
the final impurity concentration below its set specifications.
■ IMPURITIES IN CRYSTALLIZATION
An array of mechanisms of impurity incorporation into a solid
particular product exist.6−8 From literature, we identified five
principal methods of product contamination during crystal-
lization (Figure 1); agglomeration, surface deposition,
inclusions, cocrystal formation, and solid solution formation.
These methods are principally based on the location of the
impurity within the crystallization product, and may result
from several different mechanisms.
Agglomerates. When particles aggregate during a
crystallization to form larger agglomerates, pockets of
impurity-rich mother liquor can become trapped between the
intergrown particles, which then results in a substantial
impurity content of the product after secondary processing.9
General methods to avoid agglomeration include lowering the
degree of supersaturation and controlling the agitation rate,10
however more specific methods have been developed for
extreme cases. Paracetamol is known to agglomerate when
crystallized from nonpolar solvents.11 This unwanted process
can be suppressed by the application of ultrasound12 and was
found to also increase the overall impurity purge of the
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process.13 In the case of agglomeration-prone piroxicam
monohydrate, the addition of temperature cycling to a seeded
antisolvent crystallization resulted in larger, well separated
crystals.14
Surface Deposition. Impurities can be present on the
crystal surface of the final product particles. This can result
from residual mother liquor that has not been adequately
washed away in the solid−liquid separation. Additionally,
where impurities have a high affinity for the crystal surface,
adsorption onto the crystal surface can reduce crystal
purity.15−17 The addition of a methanol wash after the
filtration of β-methyl-tetra-O-acetyl-D-glucopyranuronate re-
sulted in the removal of trace residues of the α-enantiomer
present in unwashed crystals.18 In the crystallization of
bisphenol A, a different problem solving approach was taken
when the adhesion of mother liquor was found for the source
of unwanted impurity molecules: Modification of crystalliza-
tion conditions to increase overall particle size and remove
small, fine particulates allowed for improved filtration of the
product, resulting in an effective removal of the mother liquor
and with it an increase in the purity of the crystals.6
Inclusions. Macroscale impurity incorporation can also
occur through the inclusion of impurity-rich mother liquor
within the growing crystal. Growth-induced inclusions,
typically due to rapid crystal growth rates, are a function of
surface kinetics. Interactions between the API (active
pharmaceutical ingredient) crystal face and surrounding
solvent molecules can also be responsible for inclusion
formation. In the case of thiourea, crystallization from polar
solvents leads to increased macroscale, growth-induced
inclusions through electrostatic interactions with the polar
growing surface.19
Due to stirrer-particle and interparticle collisions, crystal
attrition can occur in suspensions with high energy agitation,
which leads to attrition-induced inclusions in the colliding
particles, usually only above a certain size.20 Inclusions
resulting from crystal attrition can lead to compromised
product purity. It is well documented that impurity
incorporation is a function of vessel stirring rate.21−24 When
crystallizing paracetamol from water in a 500 mL round-
bottom flask with p-acetoxyacetanilide present, increasing the
stirring speed from 200 to 320 rpm increases product purity;
however, increasing further to 400 rpm leads to higher
impurity incorporation.22
Typically, only a very small amount (<5 w%) of solvent can
be occluded,21 but this can have a significant effect on the
crystal properties. Rigorous drying processes might remove
occluded solvent with a high volatility; however, nonvolatile
impurity compounds remain captured kinetically within the
crystal. The probability of solvent encapsulation occurring
increases with crystal growth rate and final particle size and
results in particles with significant surface defects.21
Cocrystals. Novel cocrystal structures can result from
noncovalent interactions between multiple species, resulting in
regular incorporation of both compounds into the crystal
lattice. Formation of cocrystals of APIs with specifically chosen
coformers is a proven method to improve product attributes
and/or therapeutic effect, for which several reviews are
available.25−27 However, sometimes the product and an
impurity form an insoluble cocrystal. For instance, Melamine
and its hydrolysis product cyanuric acid form a toxic 1:1
cocrystal which is virtually insoluble,28 making the separation
of the two component compounds by crystallization
challenging, as the eutectic point in the ternary phase diagram
is very close to the pure component axis. Consequently, a small
amount of cocrystal will concomitantly form with one of the
pure component products.
Solid Solutions. A (partial) solid solution can form where
there are substantial similarities between crystal structures and
packing. Carbamazepine is a polymorphic API with a well-
studied solid-solution landscape. For example, carbamazepine
form V and its hydrogenated analogue share an unusual
catameric structure, and together they form solid solution
crystals.29 In the case of metastable carbamazepine form II, the
insertion of small amounts of high boiling solvents into lattice
voids provides significant thermal stabilization.30,31 As such
solid-solution formation depends on isomorphic crystal lattice
packing, it is polymorph specific. Despite the existence of
multiple polymorphs, mefenamic acid and its des-methyl
chlorinated analogue tolfenamic acid only form a solid solution
between the respective I/VI polymorphic pairing.32
Such solid-state miscibility, whereby the impurity is
thermodynamically substituted irregularly into the crystal
lattice due to structurally similarity, is characterized by a
distribution of the impurity throughout bulk crystal materi-
al.6,33 The even distribution of the impurity paracetamol in
phenacetin crystals was shown by stepwise dissolution of large
single crystals, which is hypothesized to be due to formation of
a solid solution.33 Ineffective purification of phenanthrene in
the presence of impurity 9,10-dihydroanthracene by crystal-
lization due to partial solid-solution formation between the
components was demonstrated by analysis of the binary phase
diagrams.34 Partial miscibility between a pair of α- and β-
epimers (2.6% for α in β and 4.4% for the reverse) was
revealed by construction of binary phase diagrams and
subsequent Tammann triangle plots.35 When considering the
purity required for crystalline API compounds, such low levels
of miscibility could pose an issue to the purification process.
When considering the extent of impurity incorporation is a
function of crystallization driving force, i.e. degree of
supersaturation and growth rate, the existence of solid-state
miscibility will unavoidably increase the amount of product
contamination after crystallization.
With consideration to the methods of impurity incorpo-
ration discussed, we undertook the development of a
structured approach to identify which of the mechanisms is
Figure 1. Schematic representation of various methods of low-level
impurity incorporation during crystallization.
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responsible for compromised product purity which could
generally be applied to any crystallization process.
Impurity Rejection Workflow. Figure 2 shows the
developed Impurity Rejection Workflow, considering the
identified mechanisms of impurity incorporation. The aim of
the novel workflow is to give a structured experimental
approach to identify the mechanism of impurity incorporation,
and the underlying knowledge and experimental techniques
used within the workflow can be found in literature. The
outcomes of the experimental stages are scrutinized by six
decisions, from which the identification of the mechanism
subsequently allows for a targeted mission to improve impurity
rejection for a crystalline product within specifications. The
exact definition of sufficient impurity rejection will depend on
the product to which it is being applied. During the workflow,
the crystallization behavior and product quality of the API are
investigated, and if the product impurity concentration is
higher than required, the material is subjected to a series of
experiments which become more practically laborious and
material intensive as the steps progress. Each subsequent stage
consists of simplified experimental guides to rapidly and
Figure 2. Impurity rejection workflow.
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efficiently identify or exclude a specific impurity incorporation
mechanism.
Stage 1: Baseline Knowledge. The first stage of the
workflow involves the collation of baseline knowledge required
to carry out the subsequent five stages. Specific data items are
listed in Table 1. This information is likely already available to
the user, or it may require the collection of extra physical data
or simulation results.
The first essential data item is product specification. Before
undertaking a crystallization, the user must know what product
specifications they are pursuing, including, but not limited to,
the chemical purity. In the absence of such specifications for an
API compound, current ICH guidelines require that
unidentified impurities must not be present in amounts greater
than 0.1% for a drug substance, and concentrations of
genotoxic impurities, i.e. compounds which interact with
biological processes or DNA, must be “as low as reasonably
practical”.37
The target polymorph should also be included in the
product specification. It was noted that the presence of
impurities has been reported to induce polymorphic trans-
formations during crystallization which can directly affect
impurity rejection behavior;38−40 however, this was classified
as out of scope during this work. It is assumed going forward
that the crystallization leads to the isolation of the specified
product polymorph.
As the impurity rejection workflow does not include any
steps which aid the design of a crystallization, the second
essential data item listed in Table 1 is a standard crystallization
procedure, usually following from a crystallization design
workflow. This procedure encompasses data such as the
temperature-dependent solubility of the API, and perhaps of
impurities, in the relevant solvents as well as a product
isolation procedure. This impurity rejection workflow was
formulated to complement crystallization design workflows,
such as the comprehensive continuous seeded crystallization
workflow recently reported.36
Knowledge of the physical properties of the API decides
what process conditions are practical. Specifically listed in
Table 1 are the melting point Tm and enthalpy of fusion Hfus, as
they are required for the thermal measurements conducted in
Stage 6. Similar information for the impurity material in the
system would be useful although this may not be feasible in
some applied industrial development situations, and the
workflow can be applied without knowledge of the impurity
identity. Finally, analytical methods must be available to
measure crystal purity within the limits specified.41 The most
common way to do this is using HPLC, as it offers accurate
concentration measurements for very small quantities.
Stage 2: Crystallization and Decision 1. The objective of
Stage 2 is to crystallize the API in the presence of controlled
amounts of impurities, and to determine whether these
impurities have been sufficiently rejected. The isolated product
material is then used for the experiments in the subsequent
Stages 3−5. Although the specific method of crystallization
(cooling, antisolvent, evaporative) is not crucial to the
application of the workflow, the procedure should give
reproducible product quality, yield, and purity. Therefore, a
well-thought through crystallization process should be used
that considers process conditions such as cooling profile or
addition rate in respect to nucleation and growth behavior
during the crystallization.10
There are various reported ways to determine the extent of
impurity rejection during crystallization.42−44 Here, we use the
selectivity (α) of the process. After completion of the
crystallization process, the partition of each component c
across the two phases is calculated as the experimental
distribution coefficient K using eq 1. Xs
c is the mole fraction of
the component in the solid phase after crystallization, and Xl
c is
the corresponding mole fraction in the liquid phase.
K
X
Xc
s
c
l
c=
(1)
The effectiveness of impurity removal during this crystal-
lization is subsequently determined by the selectivity α (eq 2).
K
K
i
A
α =
(2)
The ratio of the distribution coefficient Ki, of the impurity, and
the distribution coefficient KA, of the API, will usually give an α
value between 0 and 1. An α value of 0 indicates the impurity
has been completely rejected by the crystals during the process,
where a value of 1 means that the crystalline material has equal
preference to take up impurity and solute. In general, due to
the limitations of fitting a foreign molecule in a lattice, for
crystal products the selectivity is quite close to zero, leading to
low impurity concentrations in the final product. Where a solid
solution or cocrystal has formed, α will be higher. Decision 1
asks the user whether α indicates good impurity rejection, and
the criteria for this can vary depending on the specific system.
Using α also provides a method of comparing crystallization
outcomes of different APIs, impurities, and/or solvents.
The maximum allowed value for α is dictated by the purity
required and the concentration of the impurity in the
crystallization feed, which is summarized in Figure 3. For
example, to achieve a product purity of 99.0 mol % from a feed
containing 10 mol % impurity (XIMP = 0.10), the process, α ≤
0.012. If the specification is less stringent, and 95 mol % was
the required purity, α ≤ 0.122 for the same crystallization. In
practicality, the value of α should be as low as possible, and if
there are no purity specifications set, we recommend aiming
for α < 0.05. As an example, we can consider ranitidine
contaminated with N-nitrosodimethylamine. A daily dose of up
to 600 mg of ranitidine can be prescribed. When considering
the recommended safe daily ingestion level of known
contaminant N-nitrosodimethylamine is 0.096 μg per day,
and assuming N-nitrosodimethylamine is removed by crystal-
lization, ranitidine API product cannot contain more than
0.0001 mol % of the impurity. If this represents a 90% removal
Table 1. List of Prior Knowledge Required to Complete the
Workflow
Data Item Priority Method
1 Crystallization product
specification
Essential 
2 Development of
crystallization procedure
Essential Workflow36
3 Physical data of API,
including Tm and Hfus
Essential Literature search or
experimental
measurement
4 Physical data of impurities,
including Tm and Hfus
Desirable Literature search or
experimental
measurement
5 Analytical method calibration
for API and impurities
Essential e.g. HPLC
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of the impurity and a reasonable crystallization yield of 75%,
subsequently α = 0.038 (see Table S1).
Stage 3: Agglomeration Assessment and Decision 2. It is
likely that Stages 1 and 2 already in some way form part of the
user’s crystallization design workflow,36 and thus here do not
present any extra experimental undertaking. If the impurity
rejection obtained through this route is not sufficient, it is then
that this workflow can be followed to identify the mechanism
of impurity incorporation into the product. In Stage 3, the
isolated crystals are examined for agglomerates. In general,
agglomerates are unwanted (with notable exceptions, for
example spherical agglomeration45), and here they are
unwelcome due to the trapping of impurity-rich mother liquor
inclusions in the bridge between agglomerated crystalline
particles.9
Decision 2 asks the user if the crystals are significantly
agglomerated. Free-flowing particles would give a negative
answer to this question: the impurity incorporation for the
system follows another mechanism, and the user moves to
Stage 4. Should microscopy confirm the presence of
agglomerated crystals, leading to a positive outcome for
Decision 2, the workflow suggests the user return to the
crystallization stage and implement an antiagglomeration
strategy. Altering the crystallization design, for example
selection of a different solvent, performing crystallization
under a reduced supersaturation, or changing fluid dynamic
conditions, may be required in this case.14,36 A successful
antiagglomeration strategy will likely reduce the impurity
incorporation, as impurity-rich mother liquor phase cannot be
trapped between crystallized particles. Identifying agglomer-
ation is achieved by imaging the isolated particles. In this work
we have used optical microscopy, as it is an efficient,
nondestructive technique requiring little material; however,
in situ methods of imaging particles, for example the use of a
Particle Vision and Measurement (PVM) probe, would also
provide insight into whether agglomeration has occurred
during the crystallization process.
Stage 4: Surface Washing and Decision 3. Should
agglomeration not be the mechanism of impurity incorpo-
ration, the next step of the workflow investigates the extent of
impurity deposition and/or adsorption on the surface of
crystals. This occurs in the later stages of crystallization, and
unlike incorporation, the impurity does not substitute into the
crystal lattice. This results in high concentrations of impurities
at the surface of the crystal in the product, hence, requiring the
same mitigation strategy.
The concentration of impurities at the crystal surface can be
investigated through slurry experiments. Suspension and low
energy agitation of a product sample in a saturated impurity-
free API solution thoroughly washes the crystal surface to
remove impurities deposited by mother liquor and allows the
surface layers to further reject impurity molecules through
constant interaction at the crystal−solution interface. Analysis
of solid phase purity after this slurry process would show a
significant increase in purity (>50% of the impurity is
removed) if the impurity molecules are located solely in the
surface layers of the crystals. Impurity rejection in these cases
can be enhanced by fine-tuning the filtration and washing steps
after the crystallization.7 If the impurity concentration in the
solid phase remains high after this process, impurity
incorporation is not the result of surface adsorption or
deposition and the user proceeds to Stage 5.
Stage 5: Impurity Mapping and Decision 4. Stage 5
extends the knowledge gained in the surface experiments. By
creating a distribution map of the impurity throughout the bulk
crystal, it will confirm whether the impurity has been
incorporated throughout the growth of the crystals. In an
experimental method modified from recent literature,46−48
portions of pure solvent are added to a suspension of crystal
product in saturated API solution, to slowly dissolve the
contaminated crystals. The concentration change of impurity
in the liquid phase upon dissolution gives information on the
distribution of impurity throughout the crystal bulk, which is
then considered in Decision 4.
There are various outcomes of the impurity mapping
measurement, with some examples depicted in Figure 4. If
the impurity molecules are exclusively present in the outer
layers of the crystals, the impurity concentration ci will sharply
increase in the first solvent addition steps and then remain
constant (Figure 4, surface). When accompanied by a decrease
in impurity content during slurry experiments completed in
Stage 4, this result would give further support to conclude
Figure 3. Product purity required affect the maximum acceptable
value for selectivity coefficient. (Red) 99.5 mol % product purity;
(orange) 99.0 mol % product purity; (green) 98.0 mol % product
purity; (blue) 95.0 mol % product purity; all assuming 80% product
yield from the crystallization process.
Figure 4. Examples of possible impurity distribution maps. The
colored zone where the impurity reaches 100% dissolution gives an
indication of the contamination mechanism. (···) Impurity distributed
in the outer layers of the crystal. (- - -) Impurity present due
inclusions. () Impurity regularly distributed through the crystal
bulk.
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surface deposition/absorption is responsible for contamina-
tion, and the same mitigation strategy as suggested for Stage 4
should be used.
A more steady increase in impurity concentration ci which
reaches full impurity dissolution during the middle stages of
the bulk crystal dissolution would indicate significant growth-
induced or attrition-induced inclusions (Figure 4, inclusions).
The presence of inclusions can be investigated further using
imaging techniques such as high resolution microscopy.20,49,50
The distribution of macroscopic solvent inclusions in a crystal
is determined by its growth and collision history, which in turn
are strongly related to the process conditions during
crystallization. While it may be difficult to pinpoint to a
responsible inclusion formation mechanism from the impurity
mapping experiments, the dissolution trends allow the user to
prioritize subsequent experimental approaches to do so.
Strategies to alleviate solvent inclusions include reducing the
rate at which the crystallizing solution desupersaturates21 and
modifying the hydrodynamics to reduce stirrer−particle and
interparticle collisions.22
Confirming surface deposition or inclusions, i.e. where the %
impurity dissolved reaches 100% when 20−80% of the bulk
crystal has dissolved, would give a negative outcome to
Decision 4, as the impurity is present within the bulk crystals.
In the case of growth induced inclusions, growth kinetics can
have a significant negative impact on crystal purity.16,50 The
suggested mitigation strategy is to modify the process
conditions to give a different growth regime, for example
changing the supersaturation at which nucleation occurs.
Where the impurity is distributed uniformly throughout the
bulk crystal, it is likely that incorporation has occurred during
the crystal growth (Figure 4, lattice substitution).47 This would
give a positive outcome to Decision 4, and the user proceeds to
Decision 5.
Decision 5, Stage 6: Solid State Interactions and Decision
6. The objective of Stage 6 is to identify any (partial) solid
solution formation between the API and impurity, as such
behavior would impede the purification efficiency of a
crystallization. Binary phase diagrams are an effective way to
determine whether two solids are miscible in the solid state. In
a simple eutectic system, the two liquidus curves intersect at
the eutectic point, and in the absence of any solid miscibility
results in four regions in the phase diagram (Figure 5a). The
presence of partial solid miscibility to the phase diagram
introduces tie-lines indicating areas of solid solution formation
(Figure 5b). In a fully miscible system, such as a solid solution,
this eutectic point is absent as the API and impurity together
form crystalline material, competing for the same lattice
positions during growth (Figure 5d). Any formation of true
cocrystals between the API and impurity, which would also
hinder purification, will also be evident from the binary phase
diagram (Figure 5c). These situations are confirmed by the
accompanying Tammann triangle constructed from the same
data required for the binary phase diagram.51 The intersection
of two (or more, Figure 5c) linear relationships defines the true
eutectic composition, and the corresponding x-axis intercepts
denote any partial solid miscibility. This type of thermody-
namic analysis has been applied to pharmaceutical systems
with multicomponent formulations, where solid state inter-
actions are essential.52,53
As building phase diagrams is particularly material intensive,
preceding Stage 6, Decision 5 asks the user to consider
whether sufficient material is available to complete the solid-
state behavior experiments. This is a simple question, but it
may not be straightforward to answer; the absolute amount of
material required will heavily depend on the detail required. In
many applications, it is unlikely that pure impurity is available
for experimentation. However, construction of the binary
phase diagram only up to 10% impurity concentration will
likely not yield a different conclusion to a full phase diagram.
Using the methods described here, of combining dilute stock
solutions to give a range of accurate mole fractions after
evaporation, enough information to construct a useful partial
Tammann triangle can be achieved with just a few milligrams
of pure impurity, or alternatively mixtures of impure and
purified API from synthetic streams can be used to vary
impurity concentration. Where the conditions of Decision 5
are still not satisfied, a negative outcome to Decision 5 leads to
the suggestion of changing the chemistry so that this impurity
is no longer present in crude product streams in significant
concentrations. This is justified, as although the impurity
mechanism has not been identified thus far, the thermody-
namic impurity is posing a serious challenge which needs to be
mitigated.
Differential scanning calorimetry (DSC) analysis of samples
with different molar API-impurity ratios allows the exper-
imental binary phase diagram to be plotted. Inspection of this
phase diagram will indicate whether, for example, the mixtures
form a complete solid solution. Where eutectic signals are
identified in the DSC analyses, a plot of the signal enthalpy
Figure 5. Types of binary phase diagram (top) and accompanying Tammann triangle plots (bottom).51 (a) Simple eutectic with no solid solution,
(b) partial solid solution, (c) cocrystal, and (d) full solid solution.
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versus the impurity mole fraction Xi gives a Tammann triangle
plot.51 The x-axis intercept of the linear relationship between
Xi and the enthalpy of the eutectic signals corresponds to the
solid−solid miscibility gap between the API and impurity; i.e.,
an x-axis intercept of Xi = 0.05 indicates a partial miscibility of
approximately 5% of impurity with the API lattice.
After inspection of the phase diagram and Tammann triangle
plot, Decision 6 asks the user if any solid state interactions
have been identified. Each phase diagram in Figure 5 requires a
different mitigation strategy. Some strategies go beyond
adaption of crystallization design.40 A partial solid solution
concentration beyond the upper limit impurity concentration
for instance limits the achievable crystallization selectivity. The
impurity rejection issues will have to be mitigated using other
separation technologies or changes to process chemistry.
Summary of Workflow. The Impurity Rejection Workflow
depicted in Figure 2 offers a structured approach to
overcoming compromised product purity. After compiling
the background knowledge and initial crystallization, scrutiniz-
ing the chemical purity determines whether effective impurity
rejection has been achieved. The impurity concentration is not
acceptable, the extent of agglomeration is determined, which
indicates if impurity-rich mother liquor has become trapped. If
this is not the cause, the crystals are examined for deposition
and/or absorption of impurities onto the crystal surface. To
inspect further, the distribution of the impurity can be mapped
using stepwise dissolution techniques. Finally, the phase
diagram of the binary system is determined to quantify any
solid miscibility of structure, which would likely hinder
purification. The resulting knowledge gained from using this
workflow would help the user identify which impurity
mitigation strategy would most likely improve the purity of
the crystallization product in a resource efficient manner.
Case Studies. To demonstrate use of the impurity
rejection workflow, four case studies are presented. Each
system constitutes a target API to be crystallized and one
structurally related impurity. It is noted that the workflow can
be applied to systems where multiple impurities are present in
varying amounts, for example a synthetic stream output, with
little change to the experimental strategy.
Crystallizations of paracetamol (PCM) and fenofibrate
(FEN) were examined with the added structurally related
organic impurities acetanilide (ACE), metacetamol (MET),
fenofibric acid (FFA), or fenofibrate impurity E (IPE) (Figure
6). These are well-studied model compounds, and as such the
collation of baseline knowledge for Stage 1 of the workflow was
almost solely completed through literature searches. The
exception to this was the Hfus value for IPE, which was
experimentally measured using DSC (Figure S1). The results
of Stage 1 for all systems can be found in the Supporting
Information.
All cooling crystallizations for Stage 2 were carried out under
supersaturation-controlled nucleation; the specific temper-
ature-transmission profiles can be found in Figures S4−S7.
Both paracetamol and fenofibrate are polymorphic APIs, and
for all crystallizations the isolation of the targeted stable form I
polymorph was confirmed by X-ray powder diffraction
(Figures S8 and S9). Reasonable product recovery was
observed in all cases, as calculated using the literature solubility
values collated in Stage 1 (Figure S2). Each crystallization
purified the solid phase to some degree although the extent of
impurity rejection varies greatly across this short series.
Example 1: Fenofibrate−Fenofibric Acid. Fenofibrate is a
common lipid lowering medication, and the active metabolite,
Fenofibric acid, forms via ester cleavage. The required
fenofibrate purity in this work is 98.0 mol %, and the
crystallization conditions chosen give a maximum product
yield of 82.6%. This leads to a selectivity coefficient limit of
0.045.
An initial concentration of 7.64 mol % FFA is decreased to
1.63 mol % in the isolated solid phase (Table 2, entry 1),
which gives an experimental selectivity coefficient αFFA of
0.044. This low value gives a positive outcome for Decision 1,
and the goal of a crystallization with good impurity rejection is
reached.
Example 2: Fenofibrate−Impurity E. Another impurity
present in fenofibrate crystallization feeds is an analogous ethyl
Figure 6. Structures of APIs and impurities used to demonstrate the workflow; fenofibrate (FEN), fenofibric acid (FFA), fenofibrate impurity E
(IPE), paracetamol (PCM), metacetamol (MET), and acetanilide (ACE).
Table 2. Summary of Example Crystallizations Discusseda
API Impurity S fci (mol %)
sci (mol %) KA Ki α
1 FEN FFA 3.0 7.64 1.63 1.352 0.060 0.044
2 FEN IPE 3.0 9.48 6.43 1.091 0.453 0.415
3 PCM ACE 2.1 5.01 0.80 1.090 0.069 0.063
4 PCM MET 2.1 4.02 2.51 1.075 0.270 0.251
aS = relative supersaturation ratio; fci = concentration of impurity in crystallization feed;
Sci = concentration of impurity in the crystal product; KA =
experimental distribution coefficient of API; Ki = experimental distribution coefficient of the impurity; α = selectivity coefficient of crystallization.
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ester, ethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropa-
noate, named in the European Pharmacopeia as Impurity E.
A higher purity restriction of 99.8 mol % gives a lower α limit
of 0.002.
In contrast with FFA, IPE significantly contaminates
crystalline FEN after the same crystallization and isolation
procedures (Table 2, entry 2). An initial concentration of 9.48
mol % gave an impurity concentration cIPE of 6.43 mol % in
isolated FEN crystals. The corresponding selectivity coefficient
αIPE 0.415 indicates poor impurity rejection, and the material is
taken to Stage 3 of the workflow. Optical microscopy images of
the isolated material show well-separated crystals with a
prismatic morphology (see Figure 7a). As no agglomeration is
observed, Decision 2 requires the material is taken forward to
Stage 4. Surface washing did not significantly reduce the
impurity contamination of IPE in FEN (Table 3, entry 1). A
reduction of cIPE from 6.43 mol % to 4.25 mol % indicates that
a significant amount of the impurity is not dissolved into the
solution phase during the reslurry process, and therefore the
bulk crystal was examined in Stage 5.
Gradual dissolution of a sample of the contaminated FEN
crystals confirms that the impurity is dispersed within the bulk
crystal; however, the distribution is not uniform. As shown in
Figure 8, the IPE HPLC peak area% in the solution phase was
constant after the first solvent portion was added and then
increases sharply after the second. Smaller increases were
observed in subsequent steps, followed by a plateau after
approximately 60% of the suspended material has dissolved.
This latter observation suggests that, during the crystallization,
pure FEN was nucleated and began to grow, but part way
through the growth phase, IPE began substitution into the
growing crystal lattice. This indicates either thermodynamic
incorporation or significant attrition inclusions are responsible
for the compromised product purity. To investigate this
nonuniform dissolution further, this case study is taken forward
to Decision 5 and Stage 6.
Enough material was available to construct a full binary
phase diagram in Stage 6. Without being particularly
conservative with material; approximately 250 mg of pure
IPE were used to generate the binary phase diagram. The ideal
binary phase diagram (see Supporting Information) predicts a
eutectic composition of XIPE = 0.629 and a melting
temperature of 51.3 °C (Figure 9); however, crystals obtained
through isothermal evaporation of solution mixtures showed
no eutectic signals in any DSC analyses. Consequently, a
Tammann triangle cannot be constructed for the FEN−IPE
binary system.
By combining this lack of eutectic formation, with the
significant impurity concentration after crystallization and the
poor purification by reslurry in Stage 3, it was concluded that
fenofibrate and impurity E are fully miscible in the solid state,
Figure 7. Optical microscopy images of API crystals containing significant impurity concentrations. (a) Fenofibrate contaminated with 6.43 mol %
impurity E. (b) Paracetamol contaminated with 0.80 mol % acetanilide. (c) Paracetamol contaminated with 2.51 mol % metacetamol.
Table 3. Summary of Surface Washing Reslurry
Experimentsa
API Impurity sci (mol %)
swci (mol %)
1 FEN IPE 6.43 4.25
2 PCM ACE 0.80 0.27
3 PCM MET 2.51 1.17
asci = concentration of impurity in the crystal product;
swci =
concentration of impurity in the slurry product.
Figure 8. Plot showing the levels of impurity E through the bulk
fenofibrate crystalline material.
Figure 9. Experimental binary phase diagram of fenofibrate-impurity
E system. No eutectic was detected in any sample. (●) Melting peak
maxima shown with the corresponding (○) peak onset.
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forming a complete solid solution during crystallization. The
outcome of Decision 6 in the case of FEN and IPE is therefore
“yes”. The overall outcome of the workflow for this case study
is to change the crude stream composition to decrease the
concentration of IPE during crystallization. It is recommended
that the synthetic pathway should eliminate the production of
impurity E completely, as any amount present is likely to be
incorporated into the crystalline material in significant
concentrations due to solid solution formation.
Example 3: Paracetamol−Acetanilide. Acetanilide, the des-
hydroxyl analogue of paracetamol, is metabolized to aniline
and is considered a genotoxic impurity.54 Concentrations in
crystal products must be as low as possible. The product
specification in this work was 99.8 mol % crystal product
purity. The crystallization conditions used allow a maximum
possible yield of 67.0%, which leads to a maximum value for α
of 0.014.
It has been previously demonstrated that effective purging of
ACE can be achieved using a cooling crystallization from 3-
methyl-1-butanol,13 and this was also observed here in 2-
propanol. The initial acetanilide concentration cACE decreased
significantly from 5.01 mol % to 0.80 mol % (Table 2, entry 3).
The subsequent value for αACE of 0.063, while reasonably low,
is significantly higher than the allowed value, so the material is
taken forward to Stage 3. Optical microscopy images of the
isolated material are shown in Figure 7b. The image shows
free-flowing crystals which are relatively uniform in size and
shape, and therefore agglomeration is not the impurity
incorporation mechanism. Suspension of crystals in 2-propanol
saturated with PCM for 18 h decreased the concentration of
ACE from 0.80 mol % to 0.27 mol % (Table 3, entry 2). This is
a significant decrease of 66% of cACE, which gives a positive
outcome to Decision 3. Adhesion of ACE to the surface of the
PCM crystals was therefore identified as the incorporation
mechanism, and it is suggested that modification of the
isolation procedure to avoid mother liquor deposits should
provide improved PCM purity after crystallization. Indeed, a
recent study showed that a stepwise increase of the heptane
content while washing PCM crystallized in the presence of
ACE leads to enhanced product purity through efficient
removal of the impurity from the crystal surface.55 Another
possibility is that small particles of ACE crystallized as a
conglomerate toward the end of the initial process, which now
redissolve during the reslurry. This is unlikely, as the solubility
of ACE is much greater than PCM in 2-propanol.13
Example 4: Paracetamol−Metacetamol. Metacetamol is a
structural isomer of paracetamol, and while it has antipyretic
properties, it is not marketed as a medication. It is not a
paracetamol process related impurity, and was chosen here as a
model substrate due its almost identical structure to the
crystallization target. Using the same conditions as those for
the crystallization in the presence of acetanilide, a purity
specification of 99.5 mol % increased the allowed α limit to
0.042.
In concurrence with literature, metacetamol is not purged to
the same extent as acetanilide during a cooling crystallization
of paracetamol.13,44 The impurity concentration cMET de-
creased moderately from 4.02 mol % to 2.51 mol % (Table 2,
entry 4). The calculated value for αMET (0.251) is almost 6
times larger than the maximum allowed value and is consistent
with the previously reported value of 0.250 for similar
unseeded cooling crystallizations from 2-propanol.44 This
selectivity coefficient is too high to indicate good impurity
rejection, and therefore the crystallized material is taken
forward to Stage 3. The microscopy image in Figure 7b shows
similar results to ACE. The crystals are not agglomerated, so
this is not the mechanism of MET incorporation to PCM. The
slurry of crystals in 2-propanol saturated with paracetamol
decreased cMET by around 45%, leaving more than half the
initial amount of MET in the solid phase (Table 3, entry 3). A
meager reduction of cMET from 2.51 mol % to 1.17 mol % is
more suggestive of incorporation than surface deposition.
Perhaps something akin to the solid solution formation
between FEN and IPE. It is hence hypothesized at this stage
that a large part of MET is present in crystallized layers
inaccessible to the solution during surface washing, and this
example is taken forward to Stage 5.
Initial stirring of the suspension resulted in some of the
MET dissolving into the liquid phase, in corroboration with
the surface washing experiments in Stage 4; a significant
amount of the MET must be at the PCM crystal surface. As the
overall solid mass dissolves, the MET HPLC peak area of
solution increases until complete dissolution is achieved
(Figure 10). This confirms that MET is incorporated into
the crystal during the growth phase.
In order to carry out Stage 6, crystalline samples of different
PCM−MET mole fractions were prepared and analyzed by
DSC, and the melting points of the mixtures and eutectics were
plotted, along with the predicted relationship (gray lines), to
give the binary phase diagram shown in Figure 11a. Plotting
the enthalpy associated with eutectic signals (peak area) from
the same DSC results against the mole fraction gives the
corresponding Tammann triangle (Figure 11b).
The experimental depression in melting point with
increasing impurity incorporation matches well the ideal
behavior, as does the position of the eutectic. The average
eutectic melting temperature was found to be 120.7 ± 1.4 °C, a
small deviation from the predicted value of 118.6 °C (see
Figure S10). Good linear agreement is also observed in both
halves of the Tammann triangle, which give a eutectic
composition of XMET = 0.620. The aim of constructing Figure
11b was to look for any miscibility, and indeed, partial
miscibility of 6.3 ± 2.3% MET with the PCM is indicated by
the left-hand linear regression. While the absolute value is not
precise given the associated error, it can be concluded that it is
a nonzero value, and therefore MET will be present in the
crystalline phase. It can also be seen in Figure 11b that PCM is
considered not miscible with the MET, as the x-axis intercept
Figure 10. Plot showing the levels of MET through the bulk PCM
crystalline material.
Organic Process Research & Development pubs.acs.org/OPRD Article
https://dx.doi.org/10.1021/acs.oprd.0c00166
Org. Process Res. Dev. XXXX, XXX, XXX−XXX
I
of the right-hand linear regression corresponds to a
composition of 97.7 ± 3.7%. It can be inferred that
paracetamol would be efficiently purged during a crystallization
of metacetamol. Combining these two values for miscibility
introduces tie-lines to the binary phase diagram, indicated by
dashed lines in Figure 11a. The outcome of Decision 6 in the
case of paracetamol−metacetamol is therefore “yes”, and this
leads to the suggestion of changing chemistry to avoid high
impurity concentrations in the crude stream to crystallization.
During the crystallization, MET is incorporated into the
growing PCM crystal through partial miscibility and will be
very difficult to remove through a single cooling crystallization.
■ DISCUSSION
The source of impurity contamination in four representative
examples of crystallized APIs has been examined using the
workflow methodology depicted in Figure 2, all of which
resulted in different outcomes (Table 4). Baseline knowledge
(Stage 1) and crystallization (Stage 2) phases of the workflow
were straightforward in the discussed examples, as they are
well-studied model systems. Comparison of the various
selectivity coefficients determined exemplified the difference
between good and poor impurity rejection. Fenofibrate can be
purified by cooling crystallization from 2-propanol in the
presence of substantial initial concentrations of fenofibric acid
(αFFA = 0.044); however, this is more challenging in the case of
impurity E (αIPE = 0.415).
The optical microscopy images of the isolated samples in
Stage 3 ruled out agglomeration as the impurity inclusion
method for the three examples which required improved
crystal purity. The surface washing experiments completed in
Stage 4 effectively discriminated between ACE, as a kinetic
impurity deposited on the crystal surface, and IPE and MET,
which are thermodynamically incorporated into the growing
crystal.
Stage 5 confirmed that both IPE and MET were
incorporated throughout the bulk crystal phase. Stepwise
dissolution is a destructive technique; however, the valuable
knowledge gained through this experiment informs the user
that simple modification of process or isolation conditions will
not significantly improve the purification efficiency of the
crystallization. The binary phase diagrams constructed in Stage
6 revealed different behavior between the IPE-FEN and MET-
PCM systems. There was good agreement between ideal
behavior and experimental data collected for MET-PCM, and
subsequent analysis of the eutectic signals indicated partial
miscibility which makes the isolation of paracetamol as a pure
component challenging. In contrast, the experimental binary
phase diagram IPE-FEN, which deviated significantly from the
calculated ideal behavior, showed these two components are
fully miscible in the solid state, forming a solid solution. The
combination of these case studies demonstrates that by using
the workflow methodology, different impurity inclusion
mechanisms can be identified.
As this workflow applies to solution crystallization and is, in
principle, not limited to pharmaceuticals, the workflow is easily
adaptable to other areas of chemical processing and
manufacture, such as in food and agrochemical industries.
■ CONCLUSION
A workflow has been developed which allows users to identify
which impurity incorporation mechanism is responsible for a
compromised crystalline product purity following a crystal-
lization. This is supported by four pharmaceutical examples
with varied impurity inclusion behavior, demonstrating the
value of the workflow for successful discrimination between
kinetic and thermodynamic mechanisms of impurity inclusion.
The experiments that form this workflow are highly
informative, but do not necessarily require particularly
specialist knowledge or bespoke techniques. They can be
carried out using instrumentation available in most chemical
laboratories, and therefore the methodology is transferrable to
a wide range of applications. While the application of this work
to novel multicomponent systems is underway with our hands,
we invite other researchers to apply the workflow methodology
to their own crystallization development to enhance product
purity.
Figure 11. (a) Binary phase diagram for paracetamol-metacetamol,
with an average experimental eutectic temperature at 120.7 ± 1.4 °C.
(b) Tammann triangle for paracetamol−metacetamol. Left hand side
linear regression y = 249.6x − 15.0, R2 = 0.985, x-axis intercept =
0.063 ± 0.023. Right hand side linear regression y = −374.6x + 372.3,
R2 = 0.867, x-axis intercept = 0.977 ± 0.037. Intersection XMET =
0.620, Enthalpy = 139.8 J/g.
Table 4. Identified Impurity Inclusion Mechanisms in the
Case Studies, and at Which Experimental Stage This Was
Identified
Case
Study API Impurity Inclusion Mechanism
Stage
Identified
1 FEN FFA No significant inclusion 2
2 FEN IPE Solid solution formation 6
3 PCM ACE Surface deposition 3
4 PCM MET Partial solid miscibility 6
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■ MATERIALS AND METHODS
Paracetamol (≥99.0%, Sigma-Aldrich), acetanilide (99%,
Sigma-Aldrich), metacetamol (97%, Sigma-Aldrich), and
fenofibrate (≥99%, Sigma-Aldrich) were purchased and used
without further purification.56 Fenofibric acid and ethyl 2-[4-
(4-chlorobenzoyl)phenoxy]-2-methylpropanoate (fenofibrate
EP impurity E) were synthesized using literature procedures,56
and their purities were confirmed by 1H NMR spectroscopy,
HPLC, and DSC analysis. Solvents 2-propanol (99.7%, VWR
International), heptane (99%, Sigma-Aldrich), methanol
(HPLC grade, 99.9%, Sigma-Aldrich), acetonitrile (HPLC
grade, 99.9%, VWR International), acetone (99.8%, VWR
International), and ethanol (99.8%, VWR International) were
purchased and used without further purification.
Crystallization. Small scale batch crystallizations were
carried out using the Technobis Crystalline, which consists of a
metal jacket for temperature control and inline turbidity
measurement. An amount of API was weighed into an 8 mL
vial containing a magnetic stirrer bar, followed by an amount of
impurity. 2-Propanol was added to give 4 mL suspensions of
known API and impurity concentration (paracetamol 310 mg
g−1, fenofibrate 145 mg g−1). The stirred vials were then heated
above the suspension saturation temperature, held briefly
isothermally to ensure complete dissolution, and then cooled
rapidly (5 °C min−1) to the temperature to reach the desired
relative supersaturation ratio S, as defined by eq 3 where x is
the concentration (mg g−1) of the solution and x* is the
saturation concentration (mg g−1) of the system at that
temperature. The solution was held isothermally at this
temperature for 30 min, during which time nucleation
occurred, indicated by a sudden decrease in transmissivity,
and the formation of a suspension was confirmed by analysis of
in situ images. The nucleated suspension was cooled slowly
(0.5 °C min−1) to 15 °C and finally held at this final
temperature for an extended time (1.5 h for paracetamol, 3.5 h
for fenofibrate).
S
x
x
= * (3)
After crystallization, a portion of filtered mother liquor phase
was transferred to a preweighed vial, the mass was recorded,
and the solvent was evaporated from the sample using an IKA
multiwell heat block at 45 °C to give a gravimetric
concentration. The evaporated mother liquor sample was
diluted directly with mobile phase for high-performance liquid
chromatography (HPLC). The remaining suspension from the
crystallization was then vacuum filtered, and the solid was
washed with heptane (for paracetamol, 2 × 2 mL),13 or
saturated fenofibrate stock solution (fenofibrate, 2 mL). A
measured amount of the crystals isolated was diluted with
HPLC mobile phase volumetrically to a concentration within
the calibrated limits.
Solid State Analysis. HPLC was used to measure
component concentrations in the solid and isolated liquid
phases after crystallization, surface washing, and reslurry.
Calibration curves were constructed to allow accurate
concentration determination (Figure S3); however, similar
results could be obtained by using relative area%. This latter
method could be used if the impurities were not available in
their pure form for calibration, or if the identity of the
impurities is unknown. HPLC analysis was carried out using an
Agilent 1100 instrument fitted with an Agilent Poroshell 120,
EC-C18, 4.6 mm × 74 mm 2.7 μm column. For paracetamol
samples, solids were dissolved in 5% MeOH in H2O and a
mobile phase of 20% MeOH in H2O was used. An isocratic
elution of 1 mL min−1 was used, at a column temperature of 40
°C. The analysis was stopped after 12 min. For fenofibrate
samples, solids were dissolved in MeCN, and a mobile phase of
20% acidified H2O (pH = 3, acidified with H3PO4) in MeCN
was used. An isocratic elution of 1 mL min−1 was used, at a
column temperature of 25 °C. The analysis was stopped after
15 min, and between each sample an MeCN “blank” sample
was passed through the column under the same conditions.
The resulting chromatographs were analyzed using the Agilent
ChemStation software.
The polymorphic form of the API crystallized was analyzed
using a Bruker AXS D8 Advance II diffractometer using
Debye−Scherrer transmission of Cu Kα1 radiation with a
wavelength of 1.540596 Å. Samples were prepared on an
automated x-y 28 well plate with 7.5 μm Kaptopn film.
Patterns were collected in the range 4−35 2θ and were
compared to reference patterns located in the Cambridge
Crystallographic Data Centre (CCDC) to identify the
polymorph present.
Images were captured using a Leica DM6000 FS micro-
scope. Small amounts of crystals were transferred to micro-
scope slides and viewed with an appropriate magnification to
identify any agglomeration.
Differential Scanning Calorimetry (DSC) measurements
were carried out using a Netzsch DSC214 Polyma.
Experimental conditions used were based on literature
reported DSC studies of paracetamol and fenofibrate, and a
single heating−cooling cycle was used to avoid polymorphic
transformations.57,58 Samples were heated at a rate of 10 °C
min−1 to 10 °C higher than the melting temperatures of the
pure components, held isothermally for 10 min, and then
returned to room temperature at a rate of 10 °C min−1.
Using the literature reported values for the solubility of
paracetamol, metacetamol, and acetanilide in acetone,59
volumetric stock solutions of each solute with the same
molar concentration were prepared. These solutions were then
combined in different binary ratios to give solutions of
different impurity mole fractions Xi. These solutions were
evaporated at room temperature to give crystalline material
suitable for DSC analysis. The melting temperature of the
component and eutectic signals were plotted as a function of Xi
to give the experimental binary phase diagram. A similar
procedure was followed for fenofibrate using ethanol solutions,
as impurity E was found to have insufficient solubility in
acetone.
Where evaporation of the solvent gave a crystalline solid
suitable for thermal analysis, the solid was subjected to DSC
analysis. Typically, the resulting DSC graph contained two
signals, one corresponding to the component melting enthalpy
and the other corresponding to the eutectic melting enthalpy.
Typically, the component melting temperature changes
significantly with solid composition, where the eutectic melting
temperature does not. For the binary phase diagram, the
melting peak maxima of both signals were plotted as a function
of mole fraction composition. Where the DSC graphs
contained a eutectic peak, the integrated area of this signal
was plotted as a function of the impurity mole fraction Xi in the
solid phase to give the Tammann plot. A linear fit of these data
points gives two linear relationships which intersect at a
maximum energy value, with a Xi value corresponding to the
eutectic composition.51 The miscibility limit of the solid−solid
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composition is determined by the linear extrapolation to the
intersection of the Xi-axis.
Stepwise Dissolution. An amount of solid isolated from
the crystallization was suspended in a saturated API solution,
with a solid loading of approximately 100 mg mL−1, and was
stirred for at least 30 min. A filtered sample was removed (0.01
to 0.02 mL, depending on system), the mass was recorded, and
the solution was diluted directly for HPLC analysis. Portions of
pure solvent were then added to the suspension, calculated
from solubility curves to dissolve approximately 10 w% of the
material with each addition, and the suspension stirred for a
further 10−15 min, before another sample was taken and
diluted directly for HPLC analysis. This process was repeated
until the crystals were completely dissolved. The concen-
trations of the API and impurity were determined by HPLC
analysis.
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